Jason Gerberry

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported fourth-quarter sales and revenues that slightly exceeded estimates but issued a guarded outlook for 2020. The Teva Analysts BofA Securities analyst Jason Gerberry reiterated an Underperform rating on Teva and raised the price target from $8...

It appears more and more likely a case against opioid manufacturers and distributors will proceed to trial in New York state, keeping Bank of America bearish on the companies despite recent performance. The recent denial of a motion to delay the case — which the state brought against the...

Bausch Health Companies Inc (NYSE: BHC) reported Monday ahead of the market open with better-than-expected third-quarter revenue and higher non-GAAP earnings. The company also raised its fiscal year 2019 guidance. The Analyst Bank of America Merrill Lynch analyst Jason Gerberry reiterated an...

The FDA approved Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV)'s lead antibiotic asset, Xenleta, on Monday for the treatment of community-acquired bacterial infections.  The Analysts Bank of America Merrill Lynch analyst Jason Gerberry reiterated a Buy rating on...

Large-cap pharma stocks have seen a mixed performance in year to date, and among this group, Pfizer Inc. (NYSE: PFE) is poised to benefit from some key second-half catalysts, according to an analyst at Bank of America Merrill Lynch. The Analyst Jason Gerberry reiterated a Buy rating on Pfizer and...

AbbVie Inc (NYSE: ABBV) dropped Friday after falling short of fourth-quarter earnings estimates. A $1.90 bottom line missed a $1.93 estimate, and sales of $8.305 billion underperformed forecasts of $8.37 billion. The Analysts Morgan Stanley analyst David Risinger maintained an Equal-weight rating...

Cara Therapeutics Inc (NASDAQ: CARA) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. The Analyst Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Cara with a Neutral...

Multiple pharma stocks are making sympathy moves Monday in reaction to data released at the 2018 European Society of Cardiology Congress in Munich, Germany. Pfizer Inc. (NYSE: PFE) shares are trading down after the release of tafamidis data at the conference. Anylam Pharmaceuticals, Inc...

Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA) at its June 15 IPO are celebrating 13.1-percent returns. The gains should continue, in the view of two new sell-side bulls. The Ratings Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Verrica with a Buy...

Leerink has released three new reports on some Outperform-rated big-name biotech stocks that the firm’s analysts like in coming months. Here’s a look at what the analysts had to say. Gilead Sciences, Inc. (NASDAQ: GILD) Analyst Geoffrey Porges has a positive view toward the stock,...

After speaking with industry insiders and legal experts, Leerink believes that the selloff in pharmaceutical stocks is overdone. Experts see “near zero odds” that Hillary Clinton’s drug pricing plan will become law without significant changes. Leerink believes that the most...

The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." JPMorgan: Downgrading Linn Energy Gabriel Daoud of JPMorgan downgraded shares of both Linn Energy LLC (NASDAQ: LINE) and LinnCo LLC (NASDAQ:...